{"timestamp": "2026-01-17T20:46:05.613887", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6 cycles\",\"given\":\"Yes\",\"regimens\":[\"多西+顺铂\",\"多西+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"1.04 ng/ml\",\"CA125\":\"651.00 U/ml\",\"CA15-3\":\"156.00 U/ml\",\"CA19-9\":\"23.40 U/ml\",\"CEA\":\"1.13 ng/ml\",\"HE4\":\"1210.00 pmol/L\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"ROMA\":\"99.50% (premenopausal); 98.26% (postmenopausal)\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Ovarian cancer with multiple metastases (CT 2025-04-09)\",\"DIAGNOSIS\":{\"components\":[],\"histology\":\"Unknown\",\"laterality\":\"Unknown\",\"primary\":\"Ovarian cancer\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6 cycles\",\"end_date\":\"2019-08\",\"intent\":\"Adjuvant\",\"line\":\"1L\",\"regimen\":\"多西+顺铂; 多西+卡铂\",\"start_date\":\"2019-03-26\"},{\"cycles\":\"3 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"多柔比星脂质体\",\"start_date\":\"2019-11\"},{\"cycles\":\"6 cycles\",\"end_date\":\"2022-06\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"白紫+贝伐\",\"start_date\":\"2021-05\"},{\"cycles\":\"5 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"多柔比星\",\"start_date\":\"2022-07\"},{\"cycles\":\"Unknown\",\"end_date\":\"2024-09\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"口服安罗+尼拉\",\"start_date\":\"2023-01\"},{\"cycles\":\"3 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Palliative\",\"line\":\"Unknown\",\"regimen\":\"多柔比星+奈达铂\",\"start_date\":\"2024-09\"},{\"cycles\":\"1\",\"end_date\":\"Unknown\",\"intent\":\"Palliative\",\"line\":\"Unknown\",\"regimen\":\"联合免疫治疗\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"2022-06\",\"given\":\"Yes\",\"regimens\":[\"贝伐维持\"],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"No\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2019-08\",\"evidence\":\"CA125 ~110 in 2019.10\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2019-10\",\"line\":\"1L\",\"start_date\":\"2019-03-26\",\"status\":\"Unknown\"},{\"PFI_days\":\"Unknown\",\"end_date\":\"Unknown\",\"evidence\":\"CT 2025-04-09: ovarian cancer multiple metastases\",\"evidence_type\":\"Radiologic\",\"first_relapse_date\":\"2025-04-09\",\"line\":\"Unknown\",\"start_date\":\"2024-09\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2019-10\",\"evidence\":\"CA125 ~110 in 2019.10\",\"type\":\"Biochemical\"},\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2019-03-26\",\"performed\":\"Yes\",\"procedure\":\"Surgery at outside hospital; postoperative hyperthermic perfusion\"},\"VISIT_DATE\":\"2025-06-27\",\"first_relapse_date\":\"2019-10\",\"last_platinum_end_date\":\"Unknown\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2019-10\",\"flag\":\"↑\",\"value\":\"≈110\"}],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"651.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"1210.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"CA15-3\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"156.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"23.40\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"AFP\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"1.04\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"CEA\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"1.13\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"ALP\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↑\",\"value\":\"143.6\"},\"reference_range\":\"Unknown\",\"unit\":\"U/L\"},{\"analyte\":\"ALB\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"39.5\"},\"reference_range\":\"Unknown\",\"unit\":\"g/l\"},{\"analyte\":\"Hb\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"67\"},\"reference_range\":\"Unknown\",\"unit\":\"g/l\"},{\"analyte\":\"RBC\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"2.41\"},\"reference_range\":\"Unknown\",\"unit\":\"*10^12/L\"},{\"analyte\":\"WBC\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"Unknown\",\"value\":\"7.8\"},\"reference_range\":\"Unknown\",\"unit\":\"*10^9/L\"}],\"milestones\":[{\"date\":\"2019-03-26\",\"description\":\"Initial surgery at outside hospital\",\"type\":\"Surgery\"},{\"date\":\"2019-03-26\",\"description\":\"Start adjuvant chemotherapy\",\"type\":\"ChemoStart\"},{\"date\":\"2019-10\",\"description\":\"Biochemical relapse with CA125 elevation\",\"type\":\"Relapse\"},{\"date\":\"2025-04-09\",\"description\":\"CT showed multiple metastases\",\"type\":\"Imaging\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Unknown\",\"last_admin_date\":\"Unknown\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"多西+顺铂\",\"多西+卡铂\",\"多柔比星脂质体\",\"白紫+贝伐\",\"多柔比星\",\"口服安罗+尼拉\",\"多柔比星+奈达铂\",\"联合免疫治疗\",\"贝伐维持\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Ovary\",\"Multiple metastases\"],\"date\":\"2025-04-09\",\"findings\":[\"Ovarian cancer with multiple metastases\"],\"impression\":\"Ovarian cancer with multiple metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2019-03-26\",\"description\":\"Surgery at outside hospital; postoperative hyperthermic perfusion\",\"event_type\":\"Surgery\",\"key_result\":\"\",\"regimen_or_test\":\"\"},{\"date\":\"2019-08\",\"description\":\"Completed adjuvant chemotherapy; PR\",\"event_type\":\"Chemo\",\"key_result\":\"PR\",\"regimen_or_test\":\"多西+卡铂\"},{\"date\":\"2019-10\",\"description\":\"CA125 increased to ~110\",\"event_type\":\"Lab\",\"key_result\":\"≈110 U/ml\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2019-11\",\"description\":\"Salvage chemotherapy with 多柔比星脂质体, stopped due to pandemic\",\"event_type\":\"Chemo\",\"key_result\":\"3 cycles, stopped\",\"regimen_or_test\":\"多柔比星脂质体\"},{\"date\":\"2021-05\",\"description\":\"Tumor recurrence treated with 白紫+贝伐\",\"event_type\":\"Relapse\",\"key_result\":\"6 cycles; bevacizumab maintenance\",\"regimen_or_test\":\"白紫+贝伐\"},{\"date\":\"2022-06\",\"description\":\"Bevacizumab maintenance until 2022.06\",\"event_type\":\"Other\",\"key_result\":\"\",\"regimen_or_test\":\"贝伐维持\"},{\"date\":\"2022-07\",\"description\":\"多柔比星 monotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"5 cycles\",\"regimen_or_test\":\"多柔比星\"},{\"date\":\"2023-01\",\"description\":\"Oral therapy started\",\"event_type\":\"Chemo\",\"key_result\":\"\",\"regimen_or_test\":\"口服安罗+尼拉\"},{\"date\":\"2024-09\",\"description\":\"Surgery with intestinal stoma for bowel obstruction; stopped oral therapy\",\"event_type\":\"Surgery\",\"key_result\":\"\",\"regimen_or_test\":\"intestinal stoma\"},{\"date\":\"2024-09\",\"description\":\"Chemotherapy 多柔比星+奈达铂\",\"event_type\":\"Chemo\",\"key_result\":\"3 cycles\",\"regimen_or_test\":\"多柔比星+奈达铂\"},{\"date\":\"Unknown\",\"description\":\"联合免疫治疗 once, achieved SD\",\"event_type\":\"Immunotherapy\",\"key_result\":\"SD\",\"regimen_or_test\":\"联合免疫治疗\"},{\"date\":\"2025-04-09\",\"description\":\"External CT showed ovarian cancer multiple metastases\",\"event_type\":\"Imaging\",\"key_result\":\"multiple metastases\",\"regimen_or_test\":\"CT\"},{\"date\":\"2025-06-24\",\"description\":\"Biochemistry and CBC abnormalities\",\"event_type\":\"Lab\",\"key_result\":\"ALP 143.6↑; ALB 39.5↓; HGB 67 g/l↓; RBC 2.41↓\",\"regimen_or_test\":\"Biochemistry/CBC\"},{\"date\":\"2025-06-25\",\"description\":\"Tumor markers elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA125 651.00↑; HE4 1210.00↑; CA15-3 156.00↑; CA19-9 23.40; ROMA 99.50%/98.26%\",\"regimen_or_test\":\"CA125/HE4/CA15-3/CA19-9/ROMA\"}]}}", "final_output": "Final Assessment:\nHeavily pretreated metastatic ovarian cancer with severe anemia and stoma, on purely palliative trajectory; histology, biology, performance status, and exact metastatic pattern remain undefined/need urgent clarification.\n\nCore Treatment Strategy:\n- Prioritize symptom-led palliative care, including pain, nutrition, stoma support, and psychosocial/end-of-life discussions; clarify patient goals.  \n- Urgently evaluate and stabilize anemia (source, transfusion need, iron/B12/folate, hemolysis) before any further systemic therapy decisions [@20250624|14501112].  \n- Arrange updated contrast-enhanced CT/MRI with comparison to 2025-04-09 CT to define metastatic burden and complications; imaging currently outdated/limited.  \n- Retrieve and review original pathology plus archived tissue for full histology, FIGO staging, and extended biomarkers; arrange re-biopsy only if necessary.  \n\nChange Triggers:\n- If anemia and performance status improve and patient desires, reconsider low-intensity systemic options aligned strictly with palliative intent and toxicities.  \n- If imaging shows limited, complication-driving lesions (e.g., obstruction, painful metastasis), consider focused local palliation (radiation/intervention) over systemic escalation.", "initial_ops": {"chair": "- Heavily pretreated metastatic ovarian cancer with rising markers and severe anemia; intent now palliative disease control and symptom relief.  \n- Hold further cytotoxic therapy until anemia evaluated/treated and overall performance status, organ function, and symptoms documented (needs ECOG, comorbidities).  \n- Clarify current disease distribution and complication risk with updated contrast CT/MRI and prior imaging for comparison (sites, burden, obstruction, effusions).  \n- Obtain pathology report and biomarker profile including histology subtype, BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2 before systemic strategy change.  \n- Early palliative care, pain/nutrition support, transfusion assessment, and stoma function review; align next steps with patient goals and QoL.", "oncologist": "- Heavily pretreated platinum-exposed ovarian cancer with multiple metastases; current line palliative, progression suspected given rising CA125/HE4 [@20250625|13601595].  \n\n- Profound anemia (Hgb 67 g/l) may limit further cytotoxic therapy until transfusion/hematology optimization [@20250624|14501112].  \n\n- Hepatic and renal biochemistry largely acceptable; ALP mildly elevated, albumin slightly low—monitor for metastatic or nutritional impact [@20250624|14000385].  \n\n- No germline/somatic mutation data (e.g., homologous recombination, MSI, actionable targets); comprehensive molecular profiling urgently needed.  \n\n- Missing data: performance status, pain/symptom burden, prior toxicities, detailed CT report (sites/burden), and prior immunotherapy response to guide next-line choice.", "radiologist": "- CT shows ovarian malignancy with multiple metastatic sites; exact organs, lesion sizes, and counts are not specified and need updating [@IMAGING_STUDIES|2025-04-09].  \n- Overall metastatic disease burden and pattern (peritoneal vs visceral vs nodal) are undefined; require detailed current cross-sectional imaging report [unknown/needs update].  \n- No documented trend versus prior imaging; need earlier and interval scans to assess progression, stability, or response [unknown/needs update].  \n- Presence or absence of complications (bowel obstruction, ascites, hydronephrosis, thromboembolism) is not described; require updated imaging assessment [unknown/needs update].  \n- PET/CT status is unknown; clarify if performed to better define metabolic disease extent and occult metastases [unknown/needs update].", "pathologist": "- No histology, IHC, or site of disease available; definitive diagnosis, grade, and subtype are currently impossible to determine.  \n\n- Markedly elevated CA125 and HE4 with high ROMA suggest ovarian/pelvic Müllerian malignancy but are not diagnostic alone. [@MOLECULAR|2025-06-27]  \n\n- Tumor biomarkers HER2, MSI, PD-L1, TMB listed as unknown; these require dedicated tissue testing and report. [@MOLECULAR|2025-06-27]  \n\n- No germline or somatic pathogenic variants reported; comprehensive germline and tumor NGS panels appear incomplete/negative. [@MOLECULAR|2025-06-27]  \n\n- Need: surgical pathology report (primary site, histologic type, grade, FIGO stage) and IHC panel to finalize pathologic diagnosis.", "nuclear": "- No PET/CT metabolic data available for review; current PET report or images are required for staging/recurrence assessment (needs update).  \n\n- Known context: ovarian cancer with multiple metastases on prior imaging, but without metabolic characterization or current disease distribution [@IMAGING_CONTEXT|2025-04-09].  \n\n- Cannot comment on FDG uptake pattern, target lesions, or metabolic tumor volume without a contemporaneous PET/CT report (needs update).  \n\n- PET could meaningfully refine staging by clarifying extra-pelvic nodal/visceral involvement and detecting small-volume distant disease, once performed.  \n\n- For recurrence suspicion, PET would help distinguish metabolically active tumor from post-treatment change if prior therapy history and PET are provided (needs update)."}, "merged_summary": "Key Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.", "final_round_ops": {"Round 1": {"chair": "- Stabilize anemia urgently (transfusion/workup) before any further cytotoxic or intensive systemic therapy decisions [@20250624|14501112].  \n- Document ECOG, comorbidities, symptom burden, nutrition, and stoma function to refine palliative intent and treatment intensity (currently unknown).  \n- Obtain updated contrast CT/MRI with comparison to 2025‑04‑09 CT to define disease pattern and complications (details currently unknown).  \n- Retrieve/complete full pathology and molecular profile (histology, FIGO, BRCA/HRD, MSI/TMB, PD‑L1, HER2) to reassess systemic options.  \n- After anemia optimization and restaging, reconsider systemic vs best supportive care in MDT, aligned with patient goals and QoL.", "oncologist": "- Urgently investigate and correct anemia (transfusion, iron/B12/folate, bleeding/hemolysis workup) before deciding on further systemic therapy [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with report comparing to 2025-04-09 CT to define metastatic pattern and complications [@20250624|14000385].  \n\n- Retrieve full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and perform comprehensive biomarker profiling; currently unknown/needs update.  \n\n- Defer additional cytotoxic or intensive systemic therapy until anemia, ECOG status, comorbidities, symptom burden, and prior toxicities are documented; currently unknown.  \n\n- Engage palliative care for symptom control, nutritional support, and anemia management now; revisit systemic options after clinical, imaging, and molecular reassessment.", "radiologist": "- Arrange updated contrast-enhanced CT/MRI with formal report, detailing metastatic distribution, size, and complications, compared to 2025‑04‑09 CT [@IMAGING_STUDIES|2025-04-09].  \n- Reassess need for PET/CT only after updated cross-sectional imaging, focusing on whether results would alter palliative local/systemic decisions [unknown].  \n- Explicitly document presence/absence of bowel obstruction, hydronephrosis, ascites, pleural effusion, and thromboembolism on new imaging for symptom-guided care [unknown].  \n- Quantify measurable target lesions (longest diameter, organ, segment) to enable future objective radiologic response assessments if therapy resumes [unknown].  \n- Retrieve and archive all prior imaging to establish radiologic trend (progression vs stability) against new study for prognosis and planning [@IMAGING_TRENDS|2025-04-09].", "pathologist": "- Retrieve full ovarian surgical/biopsy pathology including histologic subtype, grade, FIGO stage, and IHC; currently unknown/needs update.  \n\n- Perform comprehensive biomarker testing on available tissue: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, and other actionable alterations; currently unknown.  \n\n- Confirm that existing pathology matches an ovarian/Müllerian primary and exclude other primaries or mixed histology; details unknown/needs update.  \n\n- Ensure pathology material adequacy (blocks/slides) for any planned additional molecular or IHC studies; current tissue status unknown.  \n\n- Once reports are retrieved, summarize a unified pathologic diagnosis for MDT, explicitly documenting subtype, grade, and biomarker profile.", "nuclear": "- No PET/CT available; prior metabolic imaging history and any existing PET reports remain unknown/needs update.  \n\n- Updated contrast-enhanced CT/MRI with formal report and comparison to 2025-04-09 CT is prerequisite before considering PET/CT [@IMAGING_CONTEXT|2025-04-09].  \n\n- After CT/MRI, PET/CT should be reserved for scenarios where clarifying extent or complications would change palliative systemic or local interventions.  \n\n- In this palliative, heavily pretreated setting, routine PET for staging alone is not justified without a specific, management-altering question.  \n\n- Once new CT/MRI and clinical goals are defined, re-evaluate whether PET could help distinguish active disease from treatment change or complications."}, "Round 2": {"chair": "- Prioritize anemia stabilization and etiology workup (including transfusion as needed) before any further intensive systemic therapy [@20250624|14501112].  \n- Document ECOG, comorbidities, nutrition, symptom and pain burden, and stoma function today to set realistic treatment intensity.  \n- Obtain updated contrast-enhanced CT/MRI with formal comparison to 2025-04-09 CT to define metastatic pattern and complications; defer PET/CT.  \n- Retrieve/clarify full ovarian pathology and pursue feasible biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2) or re-biopsy if necessary.  \n- Engage palliative care for symptom control, nutritional support, and anemia/stoma management; reconsider systemic options once clinical and disease status clarified.", "oncologist": "- Defer additional cytotoxic/intensive systemic therapy until anemia is evaluated/treated and ECOG, comorbidities, and symptom burden are documented; currently unknown.  \n\n- Arrange urgent anemia workup and stabilization (including transfusion consideration) before systemic decisions; Hgb 67 g/L [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with formal comparison to CT 2025-04-09 to define metastatic burden, complications, and guide palliation; details unknown.  \n\n- Retrieve/confirm original ovarian pathology (histology, grade, FIGO, IHC) and perform extended biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2); all unknown.  \n\n- Reassess systemic options after clinical stabilization, updated imaging, and pathology/molecular clarification, aligning any further treatment with palliative intent and patient goals.", "radiologist": "- Arrange updated contrast-enhanced CT or MRI, explicitly compared with 2025-04-09 CT, to define metastatic burden and complications [@IMAGING_STUDIES|2025-04-09].  \n- In the new report, detail organ sites (peritoneum, liver, lung/pleura, bone, nodes), lesion sizes, and measurable targets [unknown].  \n- Systematically document complications: bowel obstruction, bowel wall involvement, ascites, pleural effusion, hydronephrosis, biliary obstruction, pathological fractures, venous thrombosis [unknown].  \n- After reviewing updated CT/MRI, reassess whether PET/CT would add management-changing information in this palliative setting [unknown].  \n- Archive and review all prior imaging to establish radiologic trend (progression vs stability) relative to 2025-04-09 baseline [@IMAGING_TRENDS|2025-04-09].", "pathologist": "- Underlying histologic subtype, grade, FIGO stage, and IHC profile remain unknown; original ovarian pathology must be retrieved/reviewed.  \n\n- Feasibility of extended biomarkers (BRCA/HRD, MSI/TMB, PD‑L1, HER2) on existing blocks vs need for re-biopsy is unknown.  \n\n- Confirm that current metastases match the original ovarian/Müllerian primary and exclude mixed or non-gynecologic primaries once reports available.  \n\n- Verify adequacy and preservation of archived tissue (blocks/slides) for additional IHC and molecular assays before ordering expanded testing.  \n\n- After data retrieval, issue an integrated pathology summary for MDT, detailing subtype, grade, staging parameters, and full biomarker profile.", "nuclear": "- No PET/CT studies or reports are available; prior metabolic imaging history remains unknown/needs update.  \n\n- Ovarian cancer with multiple metastases is documented, but current distribution and complications await updated contrast CT/MRI [@IMAGING_CONTEXT|2025-04-09].  \n\n- At this time, PET/CT should be deferred until new CT/MRI is reviewed and a management-changing question is clearly defined.  \n\n- Once CT/MRI clarifies sites and complications, PET/CT may help in problem-solving (e.g., equivocal lesions) if it could alter palliation.  \n\n- Without imaging and pathology updates, PET cannot currently be justified for routine restaging or recurrence assessment in this palliative setting."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Given Hgb 67 g/L and unclear ECOG/symptoms, please avoid new cytotoxic/immunotherapy until anemia workup/optimization and performance status are documented; align any further systemic plan with clarified patient goals.", "radiologist": "We need a recent contrast-enhanced CT or MRI with clear description of metastatic distribution and complications, compared with prior imaging, before reconsidering systemic therapy.", "pathologist": "Please help retrieve the original surgical/biopsy pathology including histologic subtype, grade, and FIGO stage, as these are currently undocumented.", "nuclear": "PET/CT should only be proposed if you judge it likely to change management in this palliative, heavily pretreated context; otherwise, prioritize CT/MRI."}, "oncologist": {"chair": "Before planning any further systemic therapy, we need urgent clarification of performance status, anemia workup/management plan, and retrieval of full pathology plus molecular profile (BRCA/HRD, MSI/TMB, PD‑L1, HER2).", "oncologist": null, "radiologist": "Please confirm whether a recent contrast-enhanced CT with comparison is available and describe metastatic pattern/complications; advise if any additional imaging would realistically change palliative management.", "pathologist": "We need the original surgical/biopsy report with histologic subtype, grade, FIGO stage, and key IHC markers to contextualize systemic options.", "nuclear": "Only if prior imaging is inadequate or discordant, could you advise whether PET/CT is likely to alter management in this palliative, heavily pretreated setting?"}, "radiologist": {"chair": null, "oncologist": "Current imaging description is too limited for response or complication assessment; a recent contrast-enhanced CT with prior comparisons is critical.", "radiologist": null, "pathologist": null, "nuclear": "Please clarify whether a prior PET/CT was ever performed and if a new PET/CT would change management in this palliative setting."}, "pathologist": {"chair": null, "oncologist": "Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment.", "radiologist": "Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions.", "radiologist": "Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT.", "pathologist": "Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing.", "nuclear": "PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available."}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before any further systemic therapy, please prioritize urgent anemia stabilization (including transfusion plan and etiology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions.", "radiologist": "We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review.", "pathologist": "Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy.", "nuclear": "For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management."}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Before any further systemic therapy decisions, please prioritize urgent evaluation and stabilization of the severe anemia (Hgb 67 g/L) and document ECOG and current symptom burden today, as these are critical to determine treatment intensity and feasibility.", "radiologist": "Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review.", "pathologist": "Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required.", "nuclear": "For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management."}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Heavily pretreated metastatic ovarian cancer with rising markers and severe anemia; intent now palliative disease control and symptom relief.  \n- Hold further cytotoxic therapy until anemia evaluated/treated and overall performance status, organ function, and symptoms documented (needs ECOG, comorbidities).  \n- Clarify current disease distribution and complication risk with updated contrast CT/MRI and prior imaging for comparison (sites, burden, obstruction, effusions).  \n- Obtain pathology report and biomarker profile including histology subtype, BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2 before systemic strategy change.  \n- Early palliative care, pain/nutrition support, transfusion assessment, and stoma function review; align next steps with patient goals and QoL.", "timestamp": "2026-01-17T20:42:52.416192"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given Hgb 67 g/L and unclear ECOG/symptoms, please avoid new cytotoxic/immunotherapy until anemia workup/optimization and performance status are documented; align any further systemic plan with clarified patient goals.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"We need a recent contrast-enhanced CT or MRI with clear description of metastatic distribution and complications, compared with prior imaging, before reconsidering systemic therapy.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Please help retrieve the original surgical/biopsy pathology including histologic subtype, grade, and FIGO stage, as these are currently undocumented.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"PET/CT should only be proposed if you judge it likely to change management in this palliative, heavily pretreated context; otherwise, prioritize CT/MRI.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-17T20:43:13.976237"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:43:24.461841"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Stabilize anemia urgently (transfusion/workup) before any further cytotoxic or intensive systemic therapy decisions [@20250624|14501112].  \n- Document ECOG, comorbidities, symptom burden, nutrition, and stoma function to refine palliative intent and treatment intensity (currently unknown).  \n- Obtain updated contrast CT/MRI with comparison to 2025‑04‑09 CT to define disease pattern and complications (details currently unknown).  \n- Retrieve/complete full pathology and molecular profile (histology, FIGO, BRCA/HRD, MSI/TMB, PD‑L1, HER2) to reassess systemic options.  \n- After anemia optimization and restaging, reconsider systemic vs best supportive care in MDT, aligned with patient goals and QoL.", "timestamp": "2026-01-17T20:43:31.140696"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before any further systemic therapy, please prioritize urgent anemia stabilization (including transfusion plan and etiology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\",\"why\":\"conflict\"}]}", "timestamp": "2026-01-17T20:44:23.654611"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before any further systemic therapy decisions, please prioritize urgent evaluation and stabilization of the severe anemia (Hgb 67 g/L) and document ECOG and current symptom burden today, as these are critical to determine treatment intensity and feasibility.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\",\"why\":\"conflict\"}]}", "timestamp": "2026-01-17T20:44:32.521787"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Prioritize anemia stabilization and etiology workup (including transfusion as needed) before any further intensive systemic therapy [@20250624|14501112].  \n- Document ECOG, comorbidities, nutrition, symptom and pain burden, and stoma function today to set realistic treatment intensity.  \n- Obtain updated contrast-enhanced CT/MRI with formal comparison to 2025-04-09 CT to define metastatic pattern and complications; defer PET/CT.  \n- Retrieve/clarify full ovarian pathology and pursue feasible biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2) or re-biopsy if necessary.  \n- Engage palliative care for symptom control, nutritional support, and anemia/stoma management; reconsider systemic options once clinical and disease status clarified.", "timestamp": "2026-01-17T20:45:24.004298"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2025-06-27 15:54:59.567000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Stabilize anemia urgently (transfusion/workup) before any further cytotoxic or intensive systemic therapy decisions [@20250624|14501112].  \\n- Document ECOG, comorbidities, symptom burden, nutrition, and stoma function to refine palliative intent and treatment intensity (currently unknown).  \\n- Obtain updated contrast CT/MRI with comparison to 2025‑04‑09 CT to define disease pattern and complications (details currently unknown).  \\n- Retrieve/complete full pathology and molecular profile (histology, FIGO, BRCA/HRD, MSI/TMB, PD‑L1, HER2) to reassess systemic options.  \\n- After anemia optimization and restaging, reconsider systemic vs best supportive care in MDT, aligned with patient goals and QoL.\",\n    \"oncologist\": \"- Urgently investigate and correct anemia (transfusion, iron/B12/folate, bleeding/hemolysis workup) before deciding on further systemic therapy [@20250624|14501112].  \\n\\n- Obtain updated contrast-enhanced CT/MRI with report comparing to 2025-04-09 CT to define metastatic pattern and complications [@20250624|14000385].  \\n\\n- Retrieve full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and perform comprehensive biomarker profiling; currently unknown/needs update.  \\n\\n- Defer additional cytotoxic or intensive systemic therapy until anemia, ECOG status, comorbidities, symptom burden, and prior toxicities are documented; currently unknown.  \\n\\n- Engage palliative care for symptom control, nutritional support, and anemia management now; revisit systemic options after clinical, imaging, and molecular reassessment.\",\n    \"radiologist\": \"- Arrange updated contrast-enhanced CT/MRI with formal report, detailing metastatic distribution, size, and complications, compared to 2025‑04‑09 CT [@IMAGING_STUDIES|2025-04-09].  \\n- Reassess need for PET/CT only after updated cross-sectional imaging, focusing on whether results would alter palliative local/systemic decisions [unknown].  \\n- Explicitly document presence/absence of bowel obstruction, hydronephrosis, ascites, pleural effusion, and thromboembolism on new imaging for symptom-guided care [unknown].  \\n- Quantify measurable target lesions (longest diameter, organ, segment) to enable future objective radiologic response assessments if therapy resumes [unknown].  \\n- Retrieve and archive all prior imaging to establish radiologic trend (progression vs stability) against new study for prognosis and planning [@IMAGING_TRENDS|2025-04-09].\",\n    \"pathologist\": \"- Retrieve full ovarian surgical/biopsy pathology including histologic subtype, grade, FIGO stage, and IHC; currently unknown/needs update.  \\n\\n- Perform comprehensive biomarker testing on available tissue: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, and other actionable alterations; currently unknown.  \\n\\n- Confirm that existing pathology matches an ovarian/Müllerian primary and exclude other primaries or mixed histology; details unknown/needs update.  \\n\\n- Ensure pathology material adequacy (blocks/slides) for any planned additional molecular or IHC studies; current tissue status unknown.  \\n\\n- Once reports are retrieved, summarize a unified pathologic diagnosis for MDT, explicitly documenting subtype, grade, and biomarker profile.\",\n    \"nuclear\": \"- No PET/CT available; prior metabolic imaging history and any existing PET reports remain unknown/needs update.  \\n\\n- Updated contrast-enhanced CT/MRI with formal report and comparison to 2025-04-09 CT is prerequisite before considering PET/CT [@IMAGING_CONTEXT|2025-04-09].  \\n\\n- After CT/MRI, PET/CT should be reserved for scenarios where clarifying extent or complications would change palliative systemic or local interventions.  \\n\\n- In this palliative, heavily pretreated setting, routine PET for staging alone is not justified without a specific, management-altering question.  \\n\\n- Once new CT/MRI and clinical goals are defined, re-evaluate whether PET could help distinguish active disease from treatment change or complications.\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Prioritize anemia stabilization and etiology workup (including transfusion as needed) before any further intensive systemic therapy [@20250624|14501112].  \\n- Document ECOG, comorbidities, nutrition, symptom and pain burden, and stoma function today to set realistic treatment intensity.  \\n- Obtain updated contrast-enhanced CT/MRI with formal comparison to 2025-04-09 CT to define metastatic pattern and complications; defer PET/CT.  \\n- Retrieve/clarify full ovarian pathology and pursue feasible biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2) or re-biopsy if necessary.  \\n- Engage palliative care for symptom control, nutritional support, and anemia/stoma management; reconsider systemic options once clinical and disease status clarified.\",\n    \"oncologist\": \"- Defer additional cytotoxic/intensive systemic therapy until anemia is evaluated/treated and ECOG, comorbidities, and symptom burden are documented; currently unknown.  \\n\\n- Arrange urgent anemia workup and stabilization (including transfusion consideration) before systemic decisions; Hgb 67 g/L [@20250624|14501112].  \\n\\n- Obtain updated contrast-enhanced CT/MRI with formal comparison to CT 2025-04-09 to define metastatic burden, complications, and guide palliation; details unknown.  \\n\\n- Retrieve/confirm original ovarian pathology (histology, grade, FIGO, IHC) and perform extended biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2); all unknown.  \\n\\n- Reassess systemic options after clinical stabilization, updated imaging, and pathology/molecular clarification, aligning any further treatment with palliative intent and patient goals.\",\n    \"radiologist\": \"- Arrange updated contrast-enhanced CT or MRI, explicitly compared with 2025-04-09 CT, to define metastatic burden and complications [@IMAGING_STUDIES|2025-04-09].  \\n- In the new report, detail organ sites (peritoneum, liver, lung/pleura, bone, nodes), lesion sizes, and measurable targets [unknown].  \\n- Systematically document complications: bowel obstruction, bowel wall involvement, ascites, pleural effusion, hydronephrosis, biliary obstruction, pathological fractures, venous thrombosis [unknown].  \\n- After reviewing updated CT/MRI, reassess whether PET/CT would add management-changing information in this palliative setting [unknown].  \\n- Archive and review all prior imaging to establish radiologic trend (progression vs stability) relative to 2025-04-09 baseline [@IMAGING_TRENDS|2025-04-09].\",\n    \"pathologist\": \"- Underlying histologic subtype, grade, FIGO stage, and IHC profile remain unknown; original ovarian pathology must be retrieved/reviewed.  \\n\\n- Feasibility of extended biomarkers (BRCA/HRD, MSI/TMB, PD‑L1, HER2) on existing blocks vs need for re-biopsy is unknown.  \\n\\n- Confirm that current metastases match the original ovarian/Müllerian primary and exclude mixed or non-gynecologic primaries once reports available.  \\n\\n- Verify adequacy and preservation of archived tissue (blocks/slides) for additional IHC and molecular assays before ordering expanded testing.  \\n\\n- After data retrieval, issue an integrated pathology summary for MDT, detailing subtype, grade, staging parameters, and full biomarker profile.\",\n    \"nuclear\": \"- No PET/CT studies or reports are available; prior metabolic imaging history remains unknown/needs update.  \\n\\n- Ovarian cancer with multiple metastases is documented, but current distribution and complications await updated contrast CT/MRI [@IMAGING_CONTEXT|2025-04-09].  \\n\\n- At this time, PET/CT should be deferred until new CT/MRI is reviewed and a management-changing question is clearly defined.  \\n\\n- Once CT/MRI clarifies sites and complications, PET/CT may help in problem-solving (e.g., equivocal lesions) if it could alter palliation.  \\n\\n- Without imaging and pathology updates, PET cannot currently be justified for routine restaging or recurrence assessment in this palliative setting.\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nHeavily pretreated metastatic ovarian cancer with severe anemia and stoma, on purely palliative trajectory; histology, biology, performance status, and exact metastatic pattern remain undefined/need urgent clarification.\n\nCore Treatment Strategy:\n- Prioritize symptom-led palliative care, including pain, nutrition, stoma support, and psychosocial/end-of-life discussions; clarify patient goals.  \n- Urgently evaluate and stabilize anemia (source, transfusion need, iron/B12/folate, hemolysis) before any further systemic therapy decisions [@20250624|14501112].  \n- Arrange updated contrast-enhanced CT/MRI with comparison to 2025-04-09 CT to define metastatic burden and complications; imaging currently outdated/limited.  \n- Retrieve and review original pathology plus archived tissue for full histology, FIGO staging, and extended biomarkers; arrange re-biopsy only if necessary.  \n\nChange Triggers:\n- If anemia and performance status improve and patient desires, reconsider low-intensity systemic options aligned strictly with palliative intent and toxicities.  \n- If imaging shows limited, complication-driving lesions (e.g., obstruction, painful metastasis), consider focused local palliation (radiation/intervention) over systemic escalation.", "timestamp": "2026-01-17T20:46:05.613774"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Heavily pretreated platinum-exposed ovarian cancer with multiple metastases; current line palliative, progression suspected given rising CA125/HE4 [@20250625|13601595].  \n\n- Profound anemia (Hgb 67 g/l) may limit further cytotoxic therapy until transfusion/hematology optimization [@20250624|14501112].  \n\n- Hepatic and renal biochemistry largely acceptable; ALP mildly elevated, albumin slightly low—monitor for metastatic or nutritional impact [@20250624|14000385].  \n\n- No germline/somatic mutation data (e.g., homologous recombination, MSI, actionable targets); comprehensive molecular profiling urgently needed.  \n\n- Missing data: performance status, pain/symptom burden, prior toxicities, detailed CT report (sites/burden), and prior immunotherapy response to guide next-line choice.", "timestamp": "2026-01-17T20:42:55.329698"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Before planning any further systemic therapy, we need urgent clarification of performance status, anemia workup/management plan, and retrieval of full pathology plus molecular profile (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please confirm whether a recent contrast-enhanced CT with comparison is available and describe metastatic pattern/complications; advise if any additional imaging would realistically change palliative management.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"We need the original surgical/biopsy report with histologic subtype, grade, FIGO stage, and key IHC markers to contextualize systemic options.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Only if prior imaging is inadequate or discordant, could you advise whether PET/CT is likely to alter management in this palliative, heavily pretreated setting?\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:43:16.448012"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:43:25.520660"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Urgently investigate and correct anemia (transfusion, iron/B12/folate, bleeding/hemolysis workup) before deciding on further systemic therapy [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with report comparing to 2025-04-09 CT to define metastatic pattern and complications [@20250624|14000385].  \n\n- Retrieve full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and perform comprehensive biomarker profiling; currently unknown/needs update.  \n\n- Defer additional cytotoxic or intensive systemic therapy until anemia, ECOG status, comorbidities, symptom burden, and prior toxicities are documented; currently unknown.  \n\n- Engage palliative care for symptom control, nutritional support, and anemia management now; revisit systemic options after clinical, imaging, and molecular reassessment.", "timestamp": "2026-01-17T20:43:54.315104"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:25.438279"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:57.401583"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer additional cytotoxic/intensive systemic therapy until anemia is evaluated/treated and ECOG, comorbidities, and symptom burden are documented; currently unknown.  \n\n- Arrange urgent anemia workup and stabilization (including transfusion consideration) before systemic decisions; Hgb 67 g/L [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with formal comparison to CT 2025-04-09 to define metastatic burden, complications, and guide palliation; details unknown.  \n\n- Retrieve/confirm original ovarian pathology (histology, grade, FIGO, IHC) and perform extended biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2); all unknown.  \n\n- Reassess systemic options after clinical stabilization, updated imaging, and pathology/molecular clarification, aligning any further treatment with palliative intent and patient goals.", "timestamp": "2026-01-17T20:45:29.363662"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- CT shows ovarian malignancy with multiple metastatic sites; exact organs, lesion sizes, and counts are not specified and need updating [@IMAGING_STUDIES|2025-04-09].  \n- Overall metastatic disease burden and pattern (peritoneal vs visceral vs nodal) are undefined; require detailed current cross-sectional imaging report [unknown/needs update].  \n- No documented trend versus prior imaging; need earlier and interval scans to assess progression, stability, or response [unknown/needs update].  \n- Presence or absence of complications (bowel obstruction, ascites, hydronephrosis, thromboembolism) is not described; require updated imaging assessment [unknown/needs update].  \n- PET/CT status is unknown; clarify if performed to better define metabolic disease extent and occult metastases [unknown/needs update].", "timestamp": "2026-01-17T20:42:57.992718"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Current imaging description is too limited for response or complication assessment; a recent contrast-enhanced CT with prior comparisons is critical.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Please clarify whether a prior PET/CT was ever performed and if a new PET/CT would change management in this palliative setting.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:43:18.168824"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:43:26.696142"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Arrange updated contrast-enhanced CT/MRI with formal report, detailing metastatic distribution, size, and complications, compared to 2025‑04‑09 CT [@IMAGING_STUDIES|2025-04-09].  \n- Reassess need for PET/CT only after updated cross-sectional imaging, focusing on whether results would alter palliative local/systemic decisions [unknown].  \n- Explicitly document presence/absence of bowel obstruction, hydronephrosis, ascites, pleural effusion, and thromboembolism on new imaging for symptom-guided care [unknown].  \n- Quantify measurable target lesions (longest diameter, organ, segment) to enable future objective radiologic response assessments if therapy resumes [unknown].  \n- Retrieve and archive all prior imaging to establish radiologic trend (progression vs stability) against new study for prognosis and planning [@IMAGING_TRENDS|2025-04-09].", "timestamp": "2026-01-17T20:43:59.151733"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:26.756591"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:58.950136"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Arrange updated contrast-enhanced CT or MRI, explicitly compared with 2025-04-09 CT, to define metastatic burden and complications [@IMAGING_STUDIES|2025-04-09].  \n- In the new report, detail organ sites (peritoneum, liver, lung/pleura, bone, nodes), lesion sizes, and measurable targets [unknown].  \n- Systematically document complications: bowel obstruction, bowel wall involvement, ascites, pleural effusion, hydronephrosis, biliary obstruction, pathological fractures, venous thrombosis [unknown].  \n- After reviewing updated CT/MRI, reassess whether PET/CT would add management-changing information in this palliative setting [unknown].  \n- Archive and review all prior imaging to establish radiologic trend (progression vs stability) relative to 2025-04-09 baseline [@IMAGING_TRENDS|2025-04-09].", "timestamp": "2026-01-17T20:45:33.224155"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- No histology, IHC, or site of disease available; definitive diagnosis, grade, and subtype are currently impossible to determine.  \n\n- Markedly elevated CA125 and HE4 with high ROMA suggest ovarian/pelvic Müllerian malignancy but are not diagnostic alone. [@MOLECULAR|2025-06-27]  \n\n- Tumor biomarkers HER2, MSI, PD-L1, TMB listed as unknown; these require dedicated tissue testing and report. [@MOLECULAR|2025-06-27]  \n\n- No germline or somatic pathogenic variants reported; comprehensive germline and tumor NGS panels appear incomplete/negative. [@MOLECULAR|2025-06-27]  \n\n- Need: surgical pathology report (primary site, histologic type, grade, FIGO stage) and IHC panel to finalize pathologic diagnosis.", "timestamp": "2026-01-17T20:43:00.499944"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:43:19.668948"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:43:27.875632"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Retrieve full ovarian surgical/biopsy pathology including histologic subtype, grade, FIGO stage, and IHC; currently unknown/needs update.  \n\n- Perform comprehensive biomarker testing on available tissue: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, and other actionable alterations; currently unknown.  \n\n- Confirm that existing pathology matches an ovarian/Müllerian primary and exclude other primaries or mixed histology; details unknown/needs update.  \n\n- Ensure pathology material adequacy (blocks/slides) for any planned additional molecular or IHC studies; current tissue status unknown.  \n\n- Once reports are retrieved, summarize a unified pathologic diagnosis for MDT, explicitly documenting subtype, grade, and biomarker profile.", "timestamp": "2026-01-17T20:44:12.842454"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:28.120222"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:45:20.034604"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Underlying histologic subtype, grade, FIGO stage, and IHC profile remain unknown; original ovarian pathology must be retrieved/reviewed.  \n\n- Feasibility of extended biomarkers (BRCA/HRD, MSI/TMB, PD‑L1, HER2) on existing blocks vs need for re-biopsy is unknown.  \n\n- Confirm that current metastases match the original ovarian/Müllerian primary and exclude mixed or non-gynecologic primaries once reports available.  \n\n- Verify adequacy and preservation of archived tissue (blocks/slides) for additional IHC and molecular assays before ordering expanded testing.  \n\n- After data retrieval, issue an integrated pathology summary for MDT, detailing subtype, grade, staging parameters, and full biomarker profile.", "timestamp": "2026-01-17T20:45:35.895790"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- No PET/CT metabolic data available for review; current PET report or images are required for staging/recurrence assessment (needs update).  \n\n- Known context: ovarian cancer with multiple metastases on prior imaging, but without metabolic characterization or current disease distribution [@IMAGING_CONTEXT|2025-04-09].  \n\n- Cannot comment on FDG uptake pattern, target lesions, or metabolic tumor volume without a contemporaneous PET/CT report (needs update).  \n\n- PET could meaningfully refine staging by clarifying extra-pelvic nodal/visceral involvement and detecting small-volume distant disease, once performed.  \n\n- For recurrence suspicion, PET would help distinguish metabolically active tumor from post-treatment change if prior therapy history and PET are provided (needs update).", "timestamp": "2026-01-17T20:43:02.983339"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:43:21.590148"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:43:28.899052"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No PET/CT available; prior metabolic imaging history and any existing PET reports remain unknown/needs update.  \n\n- Updated contrast-enhanced CT/MRI with formal report and comparison to 2025-04-09 CT is prerequisite before considering PET/CT [@IMAGING_CONTEXT|2025-04-09].  \n\n- After CT/MRI, PET/CT should be reserved for scenarios where clarifying extent or complications would change palliative systemic or local interventions.  \n\n- In this palliative, heavily pretreated setting, routine PET for staging alone is not justified without a specific, management-altering question.  \n\n- Once new CT/MRI and clinical goals are defined, re-evaluate whether PET could help distinguish active disease from treatment change or complications.", "timestamp": "2026-01-17T20:44:15.878312"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:44:29.334525"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:45:21.377976"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.\n[R2T1 DELTA] ology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions. | chair->radiologist(missing): We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review. | chair->pathologist(missing): Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy. | chair->nuclear(conflict): For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.\n[R2T2 DELTA] nd current symptom burden today, as these are critical to determine treatment intensity and feasibility. | chair->radiologist(missing): Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review. | chair->pathologist(missing): Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required. | chair->nuclear(conflict): For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No PET/CT studies or reports are available; prior metabolic imaging history remains unknown/needs update.  \n\n- Ovarian cancer with multiple metastases is documented, but current distribution and complications await updated contrast CT/MRI [@IMAGING_CONTEXT|2025-04-09].  \n\n- At this time, PET/CT should be deferred until new CT/MRI is reviewed and a management-changing question is clearly defined.  \n\n- Once CT/MRI clarifies sites and complications, PET/CT may help in problem-solving (e.g., equivocal lesions) if it could alter palliation.  \n\n- Without imaging and pathology updates, PET cannot currently be justified for routine restaging or recurrence assessment in this palliative setting.", "timestamp": "2026-01-17T20:45:38.714359"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Heavily pretreated metastatic ovarian cancer with rising markers and severe anemia; intent now palliative disease control and symptom relief.  \\n- Hold further cytotoxic therapy until anemia evaluated/treated and overall performance status, organ function, and symptoms documented (needs ECOG, comorbidities).  \\n- Clarify current disease distribution and complication risk with updated contrast CT/MRI and prior imaging for comparison (sites, burden, obstruction, effusions).  \\n- Obtain pathology report and biomarker profile including histology subtype, BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2 before systemic strategy change.  \\n- Early palliative care, pain/nutrition support, transfusion assessment, and stoma function review; align next steps with patient goals and QoL.\",\"oncologist\":\"- Heavily pretreated platinum-exposed ovarian cancer with multiple metastases; current line palliative, progression suspected given rising CA125/HE4 [@20250625|13601595].  \\n\\n- Profound anemia (Hgb 67 g/l) may limit further cytotoxic therapy until transfusion/hematology optimization [@20250624|14501112].  \\n\\n- Hepatic and renal biochemistry largely acceptable; ALP mildly elevated, albumin slightly low—monitor for metastatic or nutritional impact [@20250624|14000385].  \\n\\n- No germline/somatic mutation data (e.g., homologous recombination, MSI, actionable targets); comprehensive molecular profiling urgently needed.  \\n\\n- Missing data: performance status, pain/symptom burden, prior toxicities, detailed CT report (sites/burden), and prior immunotherapy response to guide next-line choice.\",\"radiologist\":\"- CT shows ovarian malignancy with multiple metastatic sites; exact organs, lesion sizes, and counts are not specified and need updating [@IMAGING_STUDIES|2025-04-09].  \\n- Overall metastatic disease burden and pattern (peritoneal vs visceral vs nodal) are undefined; require detailed current cross-sectional imaging report [unknown/needs update].  \\n- No documented trend versus prior imaging; need earlier and interval scans to assess progression, stability, or response [unknown/needs update].  \\n- Presence or absence of complications (bowel obstruction, ascites, hydronephrosis, thromboembolism) is not described; require updated imaging assessment [unknown/needs update].  \\n- PET/CT status is unknown; clarify if performed to better define metabolic disease extent and occult metastases [unknown/needs update].\",\"pathologist\":\"- No histology, IHC, or site of disease available; definitive diagnosis, grade, and subtype are currently impossible to determine.  \\n\\n- Markedly elevated CA125 and HE4 with high ROMA suggest ovarian/pelvic Müllerian malignancy but are not diagnostic alone. [@MOLECULAR|2025-06-27]  \\n\\n- Tumor biomarkers HER2, MSI, PD-L1, TMB listed as unknown; these require dedicated tissue testing and report. [@MOLECULAR|2025-06-27]  \\n\\n- No germline or somatic pathogenic variants reported; comprehensive germline and tumor NGS panels appear incomplete/negative. [@MOLECULAR|2025-06-27]  \\n\\n- Need: surgical pathology report (primary site, histologic type, grade, FIGO stage) and IHC panel to finalize pathologic diagnosis.\",\"nuclear\":\"- No PET/CT metabolic data available for review; current PET report or images are required for staging/recurrence assessment (needs update).  \\n\\n- Known context: ovarian cancer with multiple metastases on prior imaging, but without metabolic characterization or current disease distribution [@IMAGING_CONTEXT|2025-04-09].  \\n\\n- Cannot comment on FDG uptake pattern, target lesions, or metabolic tumor volume without a contemporaneous PET/CT report (needs update).  \\n\\n- PET could meaningfully refine staging by clarifying extra-pelvic nodal/visceral involvement and detecting small-volume distant disease, once performed.  \\n\\n- For recurrence suspicion, PET would help distinguish metabolically active tumor from post-treatment change if prior therapy history and PET are provided (needs update).\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative for disease control and symptom relief.\n- Tumor markers (CA125, HE4) rising; progression suspected on background of multiple metastases.\n- Severe anemia (Hgb 67 g/L) currently a major limiting factor for further cytotoxic therapy; biochemistry otherwise broadly acceptable (mild ↑ALP, mild hypoalbuminemia).\n- Current imaging confirms metastatic ovarian malignancy, but exact pattern/burden/complications are undefined.\n- No accessible full pathology report, histologic subtype, or molecular profile (BRCA/HRD, MSI/TMB, PD‑L1, HER2); germline/somatic NGS essentially non-informative so far.\n\nControversies:\n- Suitability and timing of additional systemic therapy in the context of profound anemia and unknown performance status.\n- Choice and value of further lines of systemic therapy without clear histology and molecular targets.\n- Role and timing of PET/CT versus contrast CT/MRI for current restaging in a heavily pretreated, palliative context.\n\nMissing Info:\n- Clinical: ECOG performance status, comorbidities, pain and symptom burden, prior treatment toxicities, nutritional status, stoma function.\n- Imaging: Up-to-date contrast CT/MRI with detailed description of sites, size, and pattern of metastases; comparison with prior imaging; documentation of complications (obstruction, ascites, hydronephrosis, VTE). PET/CT history/status.\n- Pathology: Original surgical/biopsy report (primary site, histologic type, grade, FIGO stage), IHC panel.\n- Molecular: BRCA1/2 and broader HRD status, MSI/TMB, PD‑L1, HER2 and other actionable markers.\n- Hematology: Workup and plan for severe anemia (cause, transfusion needs, other correctable factors).\n\nWorking Plan:\n- Hold further cytotoxic therapy until anemia is evaluated and optimized and performance status/symptoms are clearly documented.\n- Arrange updated cross-sectional imaging (contrast CT/MRI) and retrieve prior scans for comparison; consider PET/CT if it will change management.\n- Obtain and review full pathology and complete molecular profiling (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Initiate or strengthen early palliative care involvement, focusing on pain, nutrition, anemia management (including transfusion assessment), and stoma function.\n- Reassess systemic treatment options once clinical status, imaging, and molecular data are clarified, aligning with the patient’s goals and quality-of-life priorities.", "timestamp": "2026-01-17T20:43:07.871417"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative for disease control and symptom relief.\n- Tumor markers (CA125, HE4) rising; progression suspected on background of multiple metastases.\n- Severe anemia (Hgb 67 g/L) currently a major limiting factor for further cytotoxic therapy; biochemistry otherwise broadly acceptable (mild ↑ALP, mild hypoalbuminemia).\n- Current imaging confirms metastatic ovarian malignancy, but exact pattern/burden/complications are undefined.\n- No accessible full pathology report, histologic subtype, or molecular profile (BRCA/HRD, MSI/TMB, PD‑L1, HER2); germline/somatic NGS essentially non-informative so far.\n\nControversies:\n- Suitability and timing of additional systemic therapy in the context of profound anemia and unknown performance status.\n- Choice and value of further lines of systemic therapy without clear histology and molecular targets.\n- Role and timing of PET/CT versus contrast CT/MRI for current restaging in a heavily pretreated, palliative context.\n\nMissing Info:\n- Clinical: ECOG performance status, comorbidities, pain and symptom burden, prior treatment toxicities, nutritional status, stoma function.\n- Imaging: Up-to-date contrast CT/MRI with detailed description of sites, size, and pattern of metastases; comparison with prior imaging; documentation of complications (obstruction, ascites, hydronephrosis, VTE). PET/CT history/status.\n- Pathology: Original surgical/biopsy report (primary site, histologic type, grade, FIGO stage), IHC panel.\n- Molecular: BRCA1/2 and broader HRD status, MSI/TMB, PD‑L1, HER2 and other actionable markers.\n- Hematology: Workup and plan for severe anemia (cause, transfusion needs, other correctable factors).\n\nWorking Plan:\n- Hold further cytotoxic therapy until anemia is evaluated and optimized and performance status/symptoms are clearly documented.\n- Arrange updated cross-sectional imaging (contrast CT/MRI) and retrieve prior scans for comparison; consider PET/CT if it will change management.\n- Obtain and review full pathology and complete molecular profiling (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Initiate or strengthen early palliative care involvement, focusing on pain, nutrition, anemia management (including transfusion assessment), and stoma function.\n- Reassess systemic treatment options once clinical status, imaging, and molecular data are clarified, aligning with the patient’s goals and quality-of-life priorities.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.", "timestamp": "2026-01-17T20:43:11.381059"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer; current intent palliative.\n- Rising CA125/HE4 with known metastases → progression likely.\n- Severe anemia (Hgb 67 g/L) is the main barrier to further cytotoxic therapy; other labs relatively preserved.\n- Imaging confirms metastatic disease but pattern, burden, and complications are not defined.\n- No complete pathology or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2) available.\n\nControversies:\n- Whether/when to pursue further systemic therapy given profound anemia and unknown performance status.\n- Value and selection of additional systemic lines without defined histology/molecular targets.\n- Optimal restaging approach (CT/MRI alone vs adding PET/CT) in a palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Recent detailed contrast CT/MRI with comparison to prior; documentation of complications; PET/CT history/status.\n- Pathology: Full surgical/biopsy report (type, grade, FIGO stage) and IHC.\n- Molecular: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, other actionable alterations.\n- Hematology: Etiology and management plan for anemia, including transfusion strategy.\n\nWorking Plan:\n- Defer further cytotoxic therapy until anemia is assessed/optimized and performance status and symptom burden documented.\n- Obtain updated contrast CT/MRI and prior imaging for comparison; consider PET/CT only if likely to alter management.\n- Retrieve full pathology and complete molecular testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review.\n- Revisit systemic treatment options once clinical status, imaging, and molecular data are available, in line with patient goals and QoL.\n[R1T1 DELTA] or PET/CT was ever performed and if a new PET/CT would change management in this palliative setting. | pathologist->oncologist(missing): Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup. | nuclear->oncologist(missing): Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment. | nuclear->radiologist(missing): Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.\n[R1T2 DELTA] chair->oncologist(safety): Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions. | chair->radiologist(missing): Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT. | chair->pathologist(missing): Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing. | chair->nuclear(missing): PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic ovarian cancer with palliative intent and likely progression (rising CA125/HE4).\n- Severe anemia (Hgb 67 g/L) is the key safety limitation; other biochemistry relatively preserved.\n- Metastatic disease confirmed but current pattern, burden, and complications are not characterized on imaging.\n- No full pathology report or molecular profile (histology, BRCA/HRD, MSI/TMB, PD‑L1, HER2), so subtype and targets remain undefined.\n\nControversies:\n- Timing and appropriateness of further systemic therapy given profound anemia and unknown performance status.\n- Choice and value of additional systemic lines without clear histology and biomarker guidance.\n- Whether PET/CT adds meaningful management-changing information beyond updated contrast CT/MRI in this palliative, heavily pretreated setting.\n\nMissing Info:\n- Clinical: ECOG, comorbidities, symptom/pain burden, prior toxicities, nutrition, stoma function.\n- Imaging: Updated, detailed contrast CT/MRI with comparison to 2025-04-09 CT, including complications; history of any prior PET/CT.\n- Pathology: Full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and completed biomarker panel (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Molecular: Confirmation of germline/somatic findings and actionable alterations.\n- Hematology: Anemia etiology and urgent stabilization plan, including transfusion.\n\nWorking Plan:\n- Urgently evaluate and stabilize anemia before any further cytotoxic/intensive systemic therapy decisions.\n- Obtain updated contrast-enhanced CT/MRI with a formal, comparative report defining disease distribution and complications.\n- Retrieve or repeat full tissue-based pathology and complete biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2).\n- Consider PET/CT only after reviewing updated CT/MRI and if results are likely to alter palliative systemic or local management.\n- Engage palliative care for symptom control, nutrition, anemia support, and stoma review; reassess systemic options once clinical, imaging, and molecular data are clarified and aligned with patient goals.", "timestamp": "2026-01-17T20:44:20.573266"}]}, "trace_events": [{"ts": "2026-01-17T20:42:09.768813", "event": "pipeline_start", "payload": {"visit_time": "2025-06-27 15:54:59.567000", "meta_info": "362201196403235065"}}, {"ts": "2026-01-17T20:42:09.769170", "event": "case_fingerprint", "payload": {"case_fingerprint": "d9b11a1ab0f2"}}, {"ts": "2026-01-17T20:42:10.036644", "event": "reports_loaded", "payload": {"lab_n": 16, "img_n": 2, "path_n": 0, "mut_n": 0, "cutoff_dt": "2025-06-28 15:54:59"}}, {"ts": "2026-01-17T20:42:16.897871", "event": "reports_selected", "payload": {"lab": {"chair": ["20250624|14000385|2025-06-24", "20250624|14501112|2025-06-24", "20250625|13601595|2025-06-25"], "oncologist": ["20250624|14000385|2025-06-24", "20250624|14501112|2025-06-24", "20250625|13601595|2025-06-25"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}}}, {"ts": "2026-01-17T20:42:45.504889", "event": "rag_query", "payload": {"query": "Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), hypoalbuminemia, prior bowel obstruction with stoma—guidance on further systemic options and goals of care?"}}, {"ts": "2026-01-17T20:42:45.504898", "event": "rag_hits", "payload": {"topk": 5, "n": 0}}, {"ts": "2026-01-17T20:42:49.730496", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-17T20:45:38.714504", "event": "mdt_discussion_end", "payload": {"merged_chars": 3934}}, {"ts": "2026-01-17T20:45:38.715138", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-17T20:46:05.613837", "event": "final_output_end", "payload": {"final_output_chars": 1267}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Global Guideline RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
